skitahoe,
I understand your point quite well about the use of other products made by big pharma which is why years ago on Seeking Alpha I wrote that big pharma diversification was needed and that consolidation was a likely outcome of bringing DCVax to the forefront. At the time Roche was way overweight with cancer products then they bought Gilead and BMY bought Celgene trying to leverage the products and research they had. Big pharma will survive but likely in a very different form due to mergers or other. At some point I believe large investment groups or a progressive government will give DCVax style safety first innovation enough support to be rewarded and moved to the forefront much more quickly than it is today. DCVax presents a unique opportunity to be invested in very significant positive change for health care world wide that is in the making.
The bigger issue for all parties concerned long term is that DCVax represents a platform, a really big platform. DCVax represents the hope of generating a proper immune response in multiple disease types from a base product that is properly activated and matured. The application of this idea goes way beyond treating cancer to treating about 80% of all diseases and can even move into the area of immunity from poisons. So you see, there is a very great deal at stake and NWBO is out front with safety and understanding of immune response.
This is going to be sooo fun to watch eyes open and jaws drop at the simplicity of learning from the natural process of immune protection that our bodies have been given that becomes compromised then restored. Kind of a Biblical theme in there somewhere about fallen nature and restoration made available at the crossroads of determination to overcome obstacles and selfless sacrifice; ). Best wishes.
Market Data 
Markets 
AI
